Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone + Clemastine vs Dexamethasone in Allergic Dermatitis
NCT01125761Phase 3Withdrawn
- Sponsor
- Azidus Laboratories Limited
- Start
- Nov 2010
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of clemastine in allergic contact dermatitis (ACD) (2 arms), sponsored by Azidus Laboratories Limited. Primary endpoint: Efficacy of the cream in improving signs and symptoms associated with allergic dermatitis at 14 days. Planned start Nov 2010; status: withdrawn.
02
Drugs
clemastine
03
Conditions
allergic contact dermatitis (ACD)
Beyond the preview
Go deeper on NCT01125761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01125761.